Two new trials published in JAMA evaluate the efficacy of periprocedural intra-arterial thrombolytics after successful endovascular thrombectomy for patients with acute ischemic stroke. Diederik Dippel, MD, PhD, of Erasmus University Medical Center discusses this and more with JAMA Deputy Editor Christopher C. Muth, MD. Related Content:

• Intra-Arterial Thrombolytics During Thrombectomy for Ischemic Stroke—End of the Story or a New Beginning?
• Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke
• Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke

Private equity acquisitions of health care facilities have rapidly increased over the past decade. However, little is known about the effects of these acquisitions on patient experience. Author Rishi K. Wadhera, MD, MPP, MPhil, of Harvard Medical School discusses this topic with JAMA Associate Editor Karen Joynt Maddox, MD, MPH. Related Content:

• Changes in Patient Care Experience After Private Equity Acquisition of US Hospitals

Certain CD4+ T-cell subtypes play a role in asthma. Characterizing asthma endotypes in diverse groups is important to help develop effective therapies for youth with asthma. Author Juan C. Celedon, MD, DrPH, University of Pittsburgh, Department of Pediatrics, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS. Related Content:

• Transcriptomic Profiles in Nasal Epithelium and Asthma Endotypes in Youth

Most Medicare Advantage (MA) plans offer dental care coverage as a supplemental benefit. However,few beneficiaries are enrolled in an MA plan that provides comprehensive dental benefits. Lisa Simon, MD, DMD, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS. Related Content:

• Availability of Dental Benefits Within Medicare Advantage Plans by Enrollment and County

Long COVID is now defined as a heterogeneous, infection-associated chronic condition present for at least 3 months after SARS-CoV-2 infection. Author Leora Horwitz, MD, MHS, of NYU Grossman School of Medicine joins JAMA Executive Editor Gregory Curfman, MD, to discuss the JAMA article "2024 Update of the RECOVER-Adult Long COVID Research Index." Related Content:

• 2024 Update of the RECOVER-Adult Long COVID Research Index
• Characterizing Long COVID in Children and Adolescents

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content:

• Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer

New antiretroviral drugs and formulations continue to become available for the prevention and management of HIV infection. Author Rajesh T. Gandhi, MD, joins JAMA Deputy Editor Preeti Malani, MD, MSJ, to discuss these new approaches for HIV. Related Content:

• Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
• Advances in Treatment and Prevention of HIV

A new JAMA study examines the association between severe maternal morbidity in a first birth and the probability of a subsequent birth. Authors Neda Razaz, PhD, and Eleni Tsamantioti, MD, MMedSc, both from the Karolinska Institute in Sweden, discuss this and more with JAMA Associate Editor Melissa A. Simon, MD, MPH. Related Content:

• Association of Severe Maternal Morbidity With Subsequent Birth
• Severe Maternal Morbidity and Subsequent Birth—Understanding and Informing a Woman’s Choice

Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:

• Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

Preterm birth is the greatest cause of neonatal mortality and morbidity, with infants born extremely preterm at highest risk. Author Brett J. Manley, PhD, the Royal Women’s Hospital, Melbourne, Australia, discusses a new study of the effect of intratracheal corticosteroid administration on survival free of bronchopulmonary dysplasia in preterm infants, with JAMA Deputy Editor Tracy A. Lieu, MD, MPH. Related Content:

• Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants